Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?

Página do item simplificado
dc.contributor.authorSantos, Igor de Andrade
dc.contributor.authorGrosche, Victoria Riquena [UNESP]
dc.contributor.authorGoulart Bergamini, Fernando Rodrigues
dc.contributor.authorSabino-Silva, Robinson
dc.contributor.authorGomes Jardim, Ana Carolina [UNESP]
dc.contributor.institutionUniversidade Federal de Uberlândia (UFU)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2020-12-10T17:59:17Z
dc.date.available2020-12-10T17:59:17Z
dc.date.issued2020-08-13
dc.description.abstractCoronaviruses (CoVs) are a group of viruses from the familyCoronaviridaethat can infect humans and animals, causing mild to severe diseases. The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a global threat, urging the development of new therapeutic strategies. Here we present a selection of relevant compounds that have been described from 2005 until now as havingin vitroand/orin vivoantiviral activities against human and/or animal CoVs. We also present compounds that have reached clinical trials as well as further discussing the potentiality of other molecules for application in (re)emergent CoVs outbreaks. Finally, through rationalization of the data presented herein, we wish to encourage further research encompassing these compounds as potential SARS-CoV-2 drug candidates.en
dc.description.affiliationUniv Fed Uberlandia, Inst Biomed Sci, Lab Virol, Uberlandia, MG, Brazil
dc.description.affiliationSao Paulo State Univ, Inst Biosci Language & Exact Sci, Sao Jose Do Rio Preto, Brazil
dc.description.affiliationUniv Fed Uberlandia, Inst Chem, Lab Synth Bioinspired Mol, Uberlandia, MG, Brazil
dc.description.affiliationUniv Fed Uberlandia, Inst Biomed Sci, Dept Physiol, Uberlandia, MG, Brazil
dc.description.affiliationUnespSao Paulo State Univ, Inst Biosci Language & Exact Sci, Sao Jose Do Rio Preto, Brazil
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG)
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipFAU/UFU
dc.description.sponsorshipIdFAPEMIG: APQ-00587-14 -SICONV 793988/2013
dc.description.sponsorshipIdFAPEMIG: APQ-02872-16
dc.description.sponsorshipIdFAPEMIG: APQ-03385-18
dc.description.sponsorshipIdCAPES: 1678329P
dc.description.sponsorshipIdCNPq: 311219/2019-5
dc.description.sponsorshipIdCNPq: CNPq465669/2014-0
dc.description.sponsorshipIdCAPES: CNPq465669/2014-0
dc.description.sponsorshipIdFAPEMIG: CNPq465669/2014-0
dc.description.sponsorshipIdCAPES: 88881.506794/2020-01
dc.format.extent23
dc.identifierhttp://dx.doi.org/10.3389/fmicb.2020.01818
dc.identifier.citationFrontiers In Microbiology. Lausanne: Frontiers Media Sa, v. 11, 23 p., 2020.
dc.identifier.doi10.3389/fmicb.2020.01818
dc.identifier.issn1664-302X
dc.identifier.urihttp://hdl.handle.net/11449/195658
dc.identifier.wosWOS:000565985000001
dc.language.isoeng
dc.publisherFrontiers Media Sa
dc.relation.ispartofFrontiers In Microbiology
dc.sourceWeb of Science
dc.subjectantivirals
dc.subjectcoronaviruses
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjecttreatment
dc.titleAntivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?en
dc.typeResenha
dcterms.rightsHolderFrontiers Media Sa

Arquivos

Coleções

Artigos